Ongoing Clinical Trials for Cerebral Arteriovenous Malformation Haemorrhagic
There is currently 1 ongoing clinical trial for patients with cerebral arteriovenous malformation haemorrhagic. This trial is investigating bevacizumab, a medication that works by reducing the growth of blood vessels, for patients who experience disabling symptoms but cannot undergo surgery or other standard treatments. The trial is being conducted in France and aims to evaluate whether this approach can improve symptoms such as chronic headaches, neurological problems, and quality of life.
Clinical trial locations
Study on Bevacizumab for Patients with Symptomatic Cerebral Arteriovenous Malformations
This trial is focused on evaluating bevacizumab as a treatment option for patients with cerebral arteriovenous malformations, which are abnormal connections between arteries and veins in the brain. These malformations can cause a range of symptoms including chronic headaches, seizures, problems with movement or sensation, and difficulties with thinking and memory.
Who can participate:
- Adults over 18 years of age
- Patients with symptomatic cerebral AVM classified as Spetzler and Martin grade III, IV, or V
- Those experiencing disabling symptoms not caused by previous bleeding, with significant impact on daily life (measured by a score greater than 1 on the modified Rankin Scale)
- Patients who cannot undergo standard treatments such as endovascular therapy, neurosurgery, or radiosurgery
- Those with normal bone marrow, liver, and kidney function
- Women of childbearing potential must have a negative pregnancy test and use effective contraception for up to 6 months after treatment ends
- Patients must provide informed consent and be affiliated with a social security plan
Who cannot participate:
- Patients who are eligible for interventional therapy
- Those not experiencing disabling symptoms
- Individuals who fall into vulnerable populations requiring special protection
What the trial involves:
The main goal of this study is to evaluate whether bevacizumab can effectively reduce disabling symptoms and improve quality of life for patients with cerebral AVMs. Bevacizumab is a monoclonal antibody that works by blocking a protein called vascular endothelial growth factor (VEGF), which is important for blood vessel growth. By inhibiting this protein, the medication may help reduce the symptoms caused by abnormal blood vessel connections in the brain.
Participants will receive intravenous infusions of bevacizumab at a dose of 5 mg per kilogram of body weight every 14 days for a period of 3 months, totaling 6 injections. Throughout the trial, regular monitoring will be conducted to assess improvements in symptoms such as chronic headaches, neurological deficits, cognitive impairment, and epilepsy. The primary evaluation occurs at 6 months and focuses on changes in cognitive and neurological scores, headache severity, and epilepsy control. Brain imaging tests using MRI will also be performed to monitor changes in the malformations and check for any side effects.
Follow-up assessments continue at 12 months to evaluate the long-term effects of treatment, including quality of life measures and monitoring for any cerebral hemorrhage or adverse events. The study compares those receiving bevacizumab with those who do not, to better understand the medication’s effectiveness in managing symptoms and improving overall well-being.
Summary
Currently, there is only one clinical trial available for patients with cerebral arteriovenous malformation haemorrhagic. This trial is being conducted in France and focuses specifically on patients who experience disabling symptoms but have limited treatment options due to the complex nature of their condition. The study investigates bevacizumab, a medication with anti-angiogenic properties that may help manage symptoms by reducing abnormal blood vessel growth. This trial represents an important research effort for patients who cannot benefit from conventional surgical or radiological interventions, potentially offering a new therapeutic avenue for this challenging condition.
